Cogent Biosciences, Inc. (formerly Unum Therapeutics Inc.) is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. The company's lead clinical program is bezuclastinib (CGT9486), a highly selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is the primary driver of systemic mastocytosis (SM), a serious disease characterized by the unchecked proliferation of mast cells. Exon 17 mutations are also key oncogenic drivers in patients with advanced gastrointestinal stromal tumors (GIST). Cogent is advancing bezuclastinib across three registration-enabling clinical programs: Non-Advanced Systemic Mastocytosis (NonAdvSM), Advanced Systemic Mastocytosis (AdvSM), and second-line GIST. Beyond bezuclastinib, the company is leveraging its discovery engine to develop a pipeline of next-generation targeted therapies, including selective inhibitors targeting ErbB2, PI3Kα, KRAS, and JAK2 V617F mutations.

Research as of 19 Jun 2026